10 Sonuçlar
BACKGROUND
The peroxisome proliferator active receptors (PPARs), members of the nuclear hormone receptor superfamily, comprise several subtypes, such as PPAR.alpha., PPAR.beta., and PPAR.gamma.. The PPAR.gamma. subtype, also referred to as PPARG, is the target of the glitazone pharmaceutical agents
BACKGROUND
The peroxisome proliferator active receptors (PPARs), members of the nuclear hormone receptor superfamily, comprise several subtypes such as PPAR.alpha., PPAR.beta., and PPAR.gamma.. The PPAR.gamma. subtype, also referred to as PPARG, is the target of the glitazone pharmaceutical agents
FIELD OF THE INVENTION
The invention generally relates to implantable medical devices, such as pacemakers or implantable cardioverter/defibrillators (ICDs), and in particular to techniques for detecting and predicting heart conditions, such as heart failure, within a patient in which a medical
DESCRIPTION
Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as medicament, and medicament containing them
The invention relates to compounds of the formula I ##STR2##
wherein R1, R2, R3 and R4 are independently of one another H, F, Cl, Br, I, CN,
Substituted 4-phenyltetra hydroisoquinolines, process for their preparation, their use as medicament, and medicament containing them.
The invention relates to compounds of the formula I ##STR2##
wherein:
R1, R2, R3 and R4 are independently of one another H, F, Cl, Br, I, CN, NO.sub.2, OH, NH.sub.2,
DESCRIPTION OF THE INVENTION
The invention relates to substituted norbornylamino derivatives having exo-configured nitrogen and an endo-fused five-, six- or seven-membered ring of the formula I, or having exo-configured nitrogen and an exo-fused five-, six- or seven-membered ring of the formula I a
This application claims the benefit of the filing date of German Patent Application Number 10063294.7-44, filed on Dec. 19, 2000, which application is hereby incorporated by reference.
One embodiment of the invention relates to substituted heterocyclo-norbomylamino derivatives having: a) an
BACKGROUND OF THE INVENTION
The present invention relates to new pharmaceutical agents for prophylaxis or treatment of diabetes mellitus comprising an insulin sensitizer and a diuretic, said diuretic having the activity of preventing or treating edema caused by the insulin sensitizer.
It is known
TECHNICAL FIELD
The present disclosure provides a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac
FIELD OF THE INVENTION
The invention generally relates to the field of deuterium-enriched pyrimidine compounds, their derivatives, enantiomers, diasteromers, solvates and pharmaceutical salts thereof for the treatment, prevention and potential cure of various diseases including chronic liver